12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-8742: Phase II started

Merck began a double-blind, placebo-controlled Phase II trial to evaluate once-daily oral MK-5172 with high- or low-dose oral MK-8742 once daily plus ribavirin for 12 weeks in about 48 patients. MK-5172 is...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >